Key facts
- Inversion Therapeutics’s last known valuation is $17.0M (Aug 2025).
- It has raised $6.9M across 1 recorded rounds; the latest was Early Stage VC ($6.9M) in Jun 2025.
- Notable investors include Red Tree Venture Capital.
- Inversion Therapeutics has filed 1 Form D with the SEC, most recently Aug 2025 ($6.9M sold to 4 investors).
- Status: Privately Held (backing).
Investors
1Free account
See the evidence behind this price
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Inversion Therapeutics
Create free account
No card required
Funding rounds
1 roundsAbout Inversion Therapeutics
Developer of an oncology biotech platform designed to discover and progress therapies against previously untapped cancer mechanisms. The company is currently operating in Stealth mode.
- Sector
- Healthcare
- HQ
- Burlingame, CA, United States
- Founded
- 2025
- Ownership
- Privately Held (backing)
PA Mark — not yet priced
Inversion Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Inversion Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
No fund marks yet
No SEC-registered fund has reported a fair-value mark on Inversion Therapeutics in its N-PORT filings yet. We sweep new filings monthly.
Pro members can request priority coverage with a 48-hour turnaround.